An Integrated Development and Manufacturing Organization (IDMO) specializing in cell therapies.
An Integrated Development and Manufacturing Organization (IDMO) specializing in cell therapies. Headquartered in South San Francisco, CA. Raised $50M in Series D funding in June 2026 led by Prime Radiant Partners.
Healthcare📍 South San Francisco, CA
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Cellares going public?
No. Cellares is private and has not filed to go public. There is no S-1 on file.
What is Cellares' valuation in 2026?
No confirmed valuation is on record for Cellares. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Cellares filed an S-1?
No public S-1 is on file for Cellares.
Who are Cellares' investors?
Cellares' investors include Prime Radiant Partners.
How much has Cellares raised?
Cellares has raised $327M in total across 1 disclosed round, most recently a Series D of $50M in Jun 2026.
Is Cellares publicly traded — can you buy Cellares stock?
No. Cellares is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Cellares on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Fabian Gerlinghaus
HQ
South San Francisco, CA
Total Raised
$327M
Last Round
Series D — $50M (Jun 2026) · Lead: Prime Radiant Partners
IPO Status
private
Fundraising Status
Series D · $50M · 3 mo ago
privateTotal raised $327M1 disclosed rounds
Secondary Market
Implied price / share
$7.57
Last round price / share
$8.51
vs last round
-11.0%
Open interest
2
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Funding History
Round
Amount
Date
Lead Investor
Post-Money
Series D
$50M
Jun 2026
Prime Radiant Partners
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Cellares — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▼ Hiring downtrend
-89% vs 2026-08
Open roles
4
via careers page
Product-build share
50%
engineering, research, product, design
Trajectory
tightening
product-led hiring — 50% of open roles build product; the rest are go-to-market and G&A.
Open roles trending down; no tracked executive churn.
Counted from Cellares's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Investors
Prime Radiant Partners
HealthcareBiotechnologyRecently Funded
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.